Dr Atul Verma (Medical Director, Heart Rhythm Program, Southlake Regional Health Centre, Newmarket, ON, Canada) spoke to us at Heart Rhythm 2019 about the current unmet needs in substrate and trigger ablation, and the findings of the STAR AF II trial.
Speaker’s disclosures: Atul Verma has received research grants from Bayer, BMS, Medtronic and Bionsense Webster, and honorarium from Abbott, Bayer and Servier.
1. What are the current unmet needs in substrate and trigger ablation? (0:06)
2. What were the findings of the Substrate and Trigger Ablation for Reduction of Atrial Fibrillation (STAR AF II) trial? (0:56)
3. How should physicians assess the need for ablation in patients with persistent atrial fibrillation, post pulmonary vein isolation? (1:57)
4. What are your highlights from Heart Rhythm 2019? (3:26)
touchCARDIO.com is an independent information resource supporting physicians, clinicians and leading industry professionals in continuously developing their knowledge, effectiveness and productivity, via free-to-access content in multimedia formats.
Share this Video
Related Videos In Atrial Fibrillation
Faizel Osman, A-A Heart Rhythm Updates 2021: 2020 ESC AF Guidelines
We spoke to Professor Faizel Osman (Consultant Cardiologist and Electrophysiologist, University Hospital Coventry and Warwickshire NHS Trust, Coventry, UK) who gave us an update about the recent new ESC Guidelines for Atrial Fibrillation and the upcoming Arrhythmia Alliance Heart Rhythm Updates 2021. Questions What are the most important new recommendations in the 2020 ESC atrial […]
Suneet Mittal, AF Symposium 2021: Atrial Fibrillation in the Post-COVID-19 Environment
We spoke to Dr Suneet Mittal (Director of Electrophysiology, The Valley Hospital, Ridgewood, NJ, USA) about the workflow innovations for atrial fibrillation ablation in the post-COVID-19 environment. Questions What have been the main challenges to atrial fibrillation (AF) ablation workflow during the COVID-19 pandemic? (0.14) What workflow innovations have been created and incorporated over the […]
Hugh Calkins, AF Symposium 2021: the STOP Persistent AF Clinical Trial
We spoke to Professor Hugh Calkins (Johns Hopkins Hospital, Baltimore, MD, USA) about the STOP Persistent AF Clinical Trial (NCT03012841). Questions: Could you tell us a little about the aims and design of the STOP Persistent AF clinical trial? (0.13) What were the findings of the study? (0.43) What are their implications for clinical practice? […]
Journal articles and more to your inbox
Get the latest clinical insights from touchCARDIOSign me up!